Introduced into clinical trials in 1963, cytosine arabinoside (1-,B-arabinofuranosyl cytosine, Ara-C) proved to be most active agent against acute leukaemia and showed lesser, but definite, activity in other cancers (Kremer, 1975) . Renewed interest in short intermittent infusion schedules of Ara-C was stimulated by a better understanding of the pharmacokinetic properties of the drug and mechanisms of tumour resistance. Such short infusion schedules would avoid the dose-limiting myelosuppressive toxicity caused by prolonged infusions (Frei et al., 1969) , and allow the administration of higher doses of Ara-C that may overcome tumour resistance (Frei & Canellos, 1980) . The positive results in patients with refractory leukaemia and lymphoma (Karenes et al., 1979; Capizzi et al., 1980; Kantarjian et al., 1983) prompted the investigation of high-dose Ara-C in patients with colorectal cancer.
Twenty-eight consecutive patients with histologically-proven measurable metastatic colorectal adenocarcinoma were treated with highdose Ara-C after informed consent was obtained. All had clear-cut evidence of progressive disease. All had prior conventional chemotherapy, 27 of them with 5-fluorouracil-containing regimens. Ninetythree percent had a performance status <2 (Table  I) Three patients had stable disease for 3, 4 and 6 months. The remaining 22 patients had progressive disease. Table II summarizes the treament-related toxicity. Myelosuppression was the dose-limiting toxicity. Neurotoxicity was minimal at the dosages used. Rebound thrombocytosis (median 821 x IO' p -1, range 625-1170 x I0 uP1-') was noted in 6 patients (23%) and occurred 3 weeks after initiation of chemotherapy, it did not result in any clinical haemostatic complications. Thrombocytopenia was usually noted 3 to 7 days earlier than granulocytopenia; patients also recovered earlier from thrombocytopenia. No delayed bone marrow recovery beyond 4 weeks was noted.
Treatment of metastatic colorectal carcinoma remains a frustrating therapeutic challenge. The response rate using agents such as 5-fluorouracil, nitrosoureas, mitomycin alone or in combination is 10 to 30%, with little improvement in survival (DeVita et al., 1982) . This indicates the need to identify new active agents or regimens for incorporation into front-line protocols. Experience with conventional Ara-C in colorectal cancer has resulted in a 10% response rate (Wasserman et al., 1975) . Similar to other antimetabolites, tumour resistance to Ara-C is relative. The rationale behind the renewed interest in high-dose Ara-C is based on the understanding of the pharmacokinetic properties, as well as the mechanisms of tumour resistance. Short infusion schedules would decrease the dose-limiting myelosuppressive toxicity. This allows the delivery of higher doses which can overcome relative tumour resistance as shown in many experimental and human tumours (Frei & Canellos, 1980) . A model using high dose Ara-C was proposed (Momparler, 1974) 
